<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869709</url>
  </required_header>
  <id_info>
    <org_study_id>APP-21-01310</org_study_id>
    <nct_id>NCT04869709</nct_id>
  </id_info>
  <brief_title>Late Preterm Corticosteroids and Neonatal Hypoglycemia</brief_title>
  <official_title>Timing of Late Preterm Corticosteroid Administration and Neonatal Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized controlled trial investigating the timing of betamethasone&#xD;
      administration in late preterm infants in relation to delivery and impact on neonatal&#xD;
      hypoglycemia. Previous data has shown that neonatal hypoglycemia is increased in late preterm&#xD;
      infants that were exposed to antenatal corticosteroids. The investigators hypothesize that&#xD;
      the timing of steroid administration may impact the development of neonatal hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of antenatal corticosteroids for women at risk for preterm delivery has become widely&#xD;
      adopted as standard of care. The American College of Obstetrics and Gynecologists (ACOG)&#xD;
      officially recommends the use of corticosteroids for pregnant women between 24 and 34 weeks&#xD;
      of gestation at risk of delivery within 7 days. Since publication of the ALPS trial, the&#xD;
      Society of Maternal Fetal Medicine (SMFM) published guidelines supporting the use of late&#xD;
      preterm steroids for singleton pregnancies between 34 weeks 0 days and 36 weeks 6 days who&#xD;
      are at high risk of preterm birth within 7 days.&#xD;
&#xD;
      A secondary finding of the ALPS trial included the observation that the administration of&#xD;
      antenatal betamethasone significantly increased the rate of neonatal hypoglycemia; the&#xD;
      authors emphasized that while the long-term risks associated with neonatal hypoglycemia are&#xD;
      not fully known, significant hypoglycemia is associated with poor neurodevelopmental outcome.&#xD;
&#xD;
      The optimal interval for administering late preterm steroids before delivery to minimize the&#xD;
      risks of hypoglycemia while maximizing the benefits of fetal lung maturity has not been&#xD;
      identified. The proposed research study will further investigate this question by randomizing&#xD;
      patients to receive late preterm corticosteroids 2 days before delivery versus 7 days before&#xD;
      delivery in order to determine if the rates and severity of neonatal hypoglycemia are&#xD;
      different.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal Glucose Concentration</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Glucose reported in mg/dL; Hypoglycemia defined as concentration &lt; 40 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Delivery to discharge from hospital</time_frame>
    <description>Days in hospital from date of delivery until date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of CPAP or High Flow Nasal Cannula</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Drop in oxygen saturation requiring use of CPAP or high flow nasal cannula for at least 12 continuous hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for supplemental oxygen</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Drop in oxygen saturation requiring use of supplemental oxygen with a fraction of inspired oxygen (FiO2) of at least 0.30 for at least 24 continuous hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of ECMO</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Drop in oxygen saturation requiring use of ECMO (extracorporeal membrane oxygenation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of mechanical ventilation</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Drop in oxygen saturation and/or inability to maintain an airway requiring use of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>From administration of the intervention (betamethasone) to delivery</time_frame>
    <description>Incidence of intrauterine fetal demise at any point after administration of the intervention (betamethasone) and before delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal death</measure>
    <time_frame>Delivery to 30 days of life</time_frame>
    <description>Death of fetus after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome (RDS)</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Defined as the presence of clinical signs of respiratory distress (ie: tachypnea, retractions, flaring, grunting, cyanosis) with a requirement of supplemental oxygen with a fraction of inspired oxygen of more than 0.21 and a chest radiograph showing hypoaeration and reticulogranular infiltrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Tachypnea of the Newborn</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Defined when tachypnea (Respiratory Rate &gt;60 breaths per minute) occurs in the absence of chest radiography or a radiograph that was normal and resolved within 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surfactant administration</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Need for administration of exogenous surfactant in the setting of neonatal respiratory distress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal pneumonia</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Defined when a combination of clinical, microbiologic, and/or radiographic findings suggest primary pulmonary infection as a cause of respiratory distress, fevers, increasing white blood cell count, need for antibiotics, and/or sepsis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Need for resuscitation at birth</measure>
    <time_frame>Within 30 minutes of delivery</time_frame>
    <description>Any intervention in the first 30 minutes, excluding blow-by oxygen</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal Hypothermia</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Defined as rectal temperature below 36 degrees Celsius</description>
  </other_outcome>
  <other_outcome>
    <measure>Necrotizing Entercolitis</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>When systemic, radiographic, and abdominal signs lead to a modified Bell stage 2 or 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraventricular Hemorrhage Grade 3 or 4 (Severe IVH)</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>Defined when the extent of brain injury includes a hemorrhage that occupies more than 50% of the lateral ventricle volume</description>
  </other_outcome>
  <other_outcome>
    <measure>Feeding Difficulty</measure>
    <time_frame>Delivery to 72 hours of life</time_frame>
    <description>inability to take all feeds by mouth, requiring gavage feeds or intravenous supplementation at least once.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Neonatal Hypoglycemia</condition>
  <condition>Prematurity</condition>
  <arm_group>
    <arm_group_label>Late Preterm Steroids 2 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Late Preterm Steroids 7 Days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Sodium Phosphate</intervention_name>
    <description>Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses</description>
    <arm_group_label>Late Preterm Steroids 2 Days</arm_group_label>
    <arm_group_label>Late Preterm Steroids 7 Days</arm_group_label>
    <other_name>Celestone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age 34 0/7 weeks to 36 5/7 weeks&#xD;
&#xD;
          -  Planned delivery in late preterm period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior course of betamethasone during pregnancy&#xD;
&#xD;
          -  Twin gestation&#xD;
&#xD;
          -  Fetal demise&#xD;
&#xD;
          -  Major fetal anomaly&#xD;
&#xD;
          -  Maternal contraindication to betamethasone&#xD;
&#xD;
          -  Pregestational diabetes&#xD;
&#xD;
          -  Expected delivery within 12 hours of randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Sasso</last_name>
    <phone>3234093536</phone>
    <email>elizabeth.sasso@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genevieve Mazza</last_name>
    <email>genevieve.mazza@med.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Sasso</last_name>
      <email>elizabeth.sasso@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Genevieve Mazza</last_name>
      <email>genevieve.mazza@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Sasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Genevieve Mazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Uquillas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Nguyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Practice Bulletin No. 159: Management of Preterm Labor. Obstet Gynecol. 2016 Jan;127(1):e29-e38. doi: 10.1097/AOG.0000000000001265. Review.</citation>
    <PMID>26695585</PMID>
  </reference>
  <reference>
    <citation>Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972 Oct;50(4):515-25.</citation>
    <PMID>4561295</PMID>
  </reference>
  <reference>
    <citation>Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, Rouse DJ, McKenna DS, Clark EA, Thorp JM Jr, Chien EK, Peaceman AM, Gibbs RS, Swamy GK, Norton ME, Casey BM, Caritis SN, Tolosa JE, Sorokin Y, VanDorsten JP, Jain L; NICHD Maternal-Fetal Medicine Units Network. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016 Apr 7;374(14):1311-20. doi: 10.1056/NEJMoa1516783. Epub 2016 Feb 4.</citation>
    <PMID>26842679</PMID>
  </reference>
  <reference>
    <citation>Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. Am J Obstet Gynecol. 2016 Aug;215(2):B13-5. doi: 10.1016/j.ajog.2016.03.013. Epub 2016 Mar 15. Review. Erratum in: Am J Obstet Gynecol. 2017 Feb;216(2):180.</citation>
    <PMID>26992737</PMID>
  </reference>
  <reference>
    <citation>Kamath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH. Antenatal corticosteroids beyond 34 weeks gestation: What do we do now? Am J Obstet Gynecol. 2016 Oct;215(4):423-30. doi: 10.1016/j.ajog.2016.06.023. Epub 2016 Jun 21. Review.</citation>
    <PMID>27342043</PMID>
  </reference>
  <reference>
    <citation>Uquillas KR, Lee RH, Sardesai S, Chen E, Ihenacho U, Cortessis VK, Barton L. Neonatal hypoglycemia after initiation of late preterm antenatal corticosteroids. J Perinatol. 2020 Sep;40(9):1339-1348. doi: 10.1038/s41372-020-0589-1. Epub 2020 Feb 14.</citation>
    <PMID>32060360</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Elizabeth Sasso</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

